exRNAdisease

Entry Detail

---



General Information

Database ID: exR0094862 RNA Name: hsa-miR-665 RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 100875075 End Site(bp): 100875094 External Links: hsa-miR-665

Disease Information

Disease Name: Benign Ovarian Disease Disease Category: Urogenital Diseases and Pregnancy Complications MeSH ID: D010049 Type: Diseases Category/Female Urogenital Diseases and Pregnancy Complications Alias: Ovarian Diseases//Disease, Ovarian//Diseases, Ovarian//Ovarian Disease

Expression Detail

GEO ID: GSE106817 Description: Integrated extracellular microRNA profiling for ovarian cancer screening Experimental Design: Cancer vs Control Case Disease Type: Benign Ovarian Disease Case Disease SubType: NA Case Sample: Benign Ovarian Disease Control Sample: Non-Cancer Number of Case: 29 Number of Control: 2759 Number of Samples: 2788

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand GINS1 chr20 25407673 25452628 + TMED10 chr14 75131469 75176612 - C19orf12 chr19 29698886 29715789 - STX6 chr1 180972712 181023121 - CTSD chr11 1752755 1764573 - CCNF chr16 2429394 2458854 + GREB1 chr2 11482341 11642788 + IRF4 chr6 391752 411443 + COX8A chr11 63974620 63976543 + ABHD2 chr15 89087459 89202355 + CLDN11 chr3 170418865 170454733 + ZNF527 chr19 37371061 37393066 + ZBTB7A chr19 4043303 4066899 - TAF5L chr1 229593111 229626047 - CIPC chr14 77098126 77117287 + C6orf120 chr6 169702190 169704856 + HADHA chr2 26190635 26244672 - EXOSC6 chr16 70246778 70251940 - TSPAN4 chr11 842812 867116 + EHD2 chr19 47713422 47743134 + KLHDC3 chr6 43014103 43021298 + CACUL1 chr10 118674167 118755249 - RBM33 chr7 155644451 155781485 + GUCD1 chr22 24540423 24555935 - ELN chr7 74027789 74069907 + RHOF chr12 121777754 121803403 - VMA21 chrX 151396515 151409364 + CBFB chr16 67028984 67101058 + STX3 chr11 59713456 59805882 + TNFRSF1B chr1 12166991 12209228 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000417 chr12 69644908 69656342 + hsa_circ_0000402 chr12 53670403 53671011 + hsa_circ_0000798 chr17 65941524 65944422 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0001387 chr4 1902352 1936989 + hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005394.2 chr19 28435388 28727680 - AC018521.1 chr17 47945424 47981736 + AC023509.1 chr12 53441741 53467528 + AC118758.3 chr7 56809214 56848800 - AC234582.1 chr1 155195004 155205495 + AL355987.4 chr9 136799223 136810042 + ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - LINC00665 chr19 36313067 36331770 - LINC00910 chr17 43338741 43389199 - LINC01089 chr12 121795267 121803906 - LINC01535 chr19 37251885 37265535 + MIR29B2CHG chr1 207801518 207879115 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + SND1-IT1 chr7 127997597 128000077 + SNHG16 chr17 76557764 76565348 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE106817 Sample Source: Blood Source Fraction: Serum Platform: GPL21263 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2535 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). RNA library preparation protocol: miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.

Reference

PMID: 30333487 Title: Integrated extracellular microRNA profiling for ovarian cancer screening Author: Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T Journal: Nat Commun. 2018 Oct 17;9(1):4319. Description: to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.